According to @StockMKTNewz, Novo Nordisk (NYSE: NVO) is planning to target approximately 15 million new patients as Medicare prepares to include weight loss drugs under its coverage. This strategic move could significantly expand Novo Nordisk's market reach and boost its revenue streams, making it a key development for investors to monitor.